|
|
Vaccine Detail
|
Pfs25 VLP-FhCMB |
| Vaccine Information |
- Vaccine Name: Pfs25 VLP-FhCMB
- Target Pathogen: Plasmodium spp.
- Target Disease: Malaria
- Type: Subunit vaccine
- Status: Licensed
- Host Species for Licensed Use: None
- Antigen: Pfs25: is a member of a Plasmodium protein family characterized by the presence of epidermal growth factor (EGF)-like repeat motifs, numerous cysteine residues and a complex tertiary structure. (Chichester et al., 2018)
- Pfs25 from P. falciparum 3D7
gene engineering:
- Type: Recombinant protein preparation
- Description: Pfs25 is used as the malaria vaccine antigen.
- Detailed Gene Information: Click Here.
- Preparation: Pfs25 VLP-FhCMB, a chimeric non-enveloped VLP comprising Pfs25 fused to the Alfalfa mosaic virus coat protein (CP), produced in hydroponically grown Nicotiana benthamiana plants using a Tobacco mosaic virus (TMV)-based hybrid vector, then purified and characterized. 400 µg of total protein per mL in an aqueous formulation containing 50 mM sodium phosphate. Four total protein dose levels of the vaccine (2, 10, 30 and 100 μg per 0.5 mL) were formulated in the clinic on the day of administration with 0.3% Alhydrogel (Chichester et al., 2018)
- Immunization Route: Intramuscular injection (i.m.)
- Description: Pfs25 VLP-FhCMB is a plant-produced Pfs25 virus-like particle usedas a transmission blocking vaccine against malaria
|
| Host Response |
|
|
| References |
Chichester et al., 2018: Chichester JA, Green BJ, Jones RM, Shoji Y, Miura K, Long CA, Lee CK, Ockenhouse CF, Morin MJ, Streatfield SJ, Yusibov V. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults. Vaccine. 2018; 36(39); 5865-5871. [PubMed: 30126674].
|
|
